Novavax gains on continued optimism over its RSV vaccine

|By:, SA News Editor

Novavax (NVAX +4.9%) gains on renewed optimism that the company may announce positive news on its Respiratory Syncytial Virus Fusion Vaccine at its annual Analyst Day on September 24.

Last week Lazard upped its price target on the shares to $11, saying the vaccine was "one of the more under-appreciated assets in the industry."

The firm thinks NVAX's drug could be more effective than its competitor, Synagis.

Additionally, Italian veterinary authorities have reported an outbreak of highly pathogenic avian influenza at a commercial poultry farm in Emilia-Romagna, an administrative region in Northern Italy.